Allogeneic bone marrow transplantation (BMT) is the only effective treatment for hematologic malignancies resistant t o conventional chemotherapy. Until recently, no cure existed for patients who relapsed post-BMT. We present our long-term observations on remission induction, after relapse post-BMT, by allogeneic cell therapy (allo-CT) and the feasibility of remission induction in allo-CT-resistant patients by activation of antileukemia effector cells with recombinant human interleukin-2 (rhlL-2) in vitro and in vivo. The longest observation of successful allo-CT (event-free survival, greater than 8 years) was made in a patient with resistant pre-B lymphoblastic leukemia who received infusions with graded increments of donor (female) peripheral blood lymphocytes (PBL) as soon as bulky hematologic and extramedullary relapse was noticed early post-BMT. The patient is currently without evidence of residual host (male) cells as determined by polymerase chain reaction (PCR). Of 17 patients with acute and chronic leukemia in relapse after BMT, l 0 were reinduced into complete remission. Four patients IGH-DOSE chemoradiotherapy followed by bone marrow transplantation (BMT) with cells from genotypically or phenotypically matched donors has become the treatment of choice for chronic myeloid leukemia (CML), for patients with acute leukemia who have already relapsed or who are at high risk to relapse, and for those with primary resistant di~ease.'.~ The advantage of BMT over conventional chemotherapy lies in the combined effects of the higher myeloablative dose of chemoradiotherapy given pretransplant and the ability of immunocompetent allogeneic donor T lymphocytes to react to residual tumor cells of host origin, ie, the graft-versus-leukemia (GVL) effect!"' The possibility that allogeneic BMT eliminates leukemia through immune-mediated GVL effects has been suggested ever since the earliest days of e~perimental~"~ and clinical BMT.4" Recent data from murine models imply that GVL effects may also be induced by posttransplant administration of graded increments of immunocompetent allogeneic lymphocytesI6-" and may be additionally increased by in vivo activation of lymphocytes with recombinant human interleukin-2 (rhIL-2).'6-2" Preliminary data from pilot clinical trials suggest that a similar rationale for the treatment and prevention of relap~e'"~' may be applicable. The present report documents the first successful induction of GVL effects by allogeneic cell therapy (allo-CT) using donor peripheral blood lymphocytes (PBL) in a patient with resistant acute lymphoblastic leukemia (ALL) who relapsed shortly after BMT. Similar cases with a variety of malignant hematologic diseases have been successfully treated at many BMT centers, including our own. The cumulative international data indicate that cell therapy using major histocompatibility complex (MHC)-matched allogeneic lymphocytes should be considered the treatment of choice for persistent disease or relapse post-BMT. Moreover, our data show that patients with tumor cells resistant to allo-CT can still respond to in vivo 2 in vitro activation of donor PBL by rhIL-2. with cytogenetic relapse responded t o allo-CT alone, while five of six patients with overt hematologic relapse responded only after additional activation of donor with rhlL-2. Allo-CT can, therefore, successfully reverse chemoradiotherapy-resistant relapse of both acute and chronic leukemia. Moreover, in patients resistant t o donor lymphocyte infusion, remission can be accomplished by additionally activating donor PBL in vitro and/or in vivo with rhlL-2. Based on our observations, after BMT, allo-CT should be considered the treatment of choice for patients with hematologic malignancies resistant t o conventional anticancer modalities. Allogeneic activated cell therapy (allo-ACT) should be considered for patients with tumor cells resistant t o allo-CT. Although allo-CT, followed if indicated by allo-ACT, can be effective for patients with overt hematologic relapse, reversal of persistant minimal residual disease or documented molecular/cytogenetic relapse early after BMT may also be considered as a possible indication for allo-CT.
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MATERIALS AND METHODS

Patient characteristics.
A total of 17 patients (age range, 2.5 to 39 years; median, 17 years) are presented: six with ALL, three with acute myeloid leukemia (AML), six with CML (two in accelerated phase), one with Burkitt's lymphoma, and one with myelodysplastic syndrome (MDS) with excess blasts. All patients gave their informed consent after approval of the proposed study by the Institutional Review Board (Helsinki Committee). Patient characteristics and details of all pretransplant and posttransplant therapies are listed in Table 1 for 13 patients with overt hematologic relapse and in Table  2 for four patients with minimal cytogenetic relapse. All patients received BMT from a serologically HLA-A,B,DR-matched, MLR nonreactive sibling. PBL were obtained from the marrow donor.
BMT procedures. The three conditioning regimens used before BMT were (1) cyclophosphamide 60 mgkg X 2 days followed by fractionated total body irradiation (TBI) 200 cGy X six fractions (protocol in use for patients with CML); (2) etoposide 1,500 mg/m' X 1 day, cyclophosphamide 60 mgkg X 1 day, melphalan 60 mgl m' X 1 day followed by T B 1 200 cGy X 6 over 3 days (protocol in use for patients with acute leukemia); and (3) combination chemo- Tables 1 and 2 , respectively. No prior treatment with alpha-interferon (aIFN) was given before allo-CT.
Immunotherapy with allogeneic donor PBL Allo-CT was initiated by infusion with graded increments of donor PBL (Fig 1) . Eligibility criteria included patients with documented relapse or no immunosuppressive agents, with no evidence of GVHD in the immediate posttransplant period. In patients with relapse resistant to infusion with donor PBL and no severe GVHD, allo-CT was combined with in vivo administration of -2.
Allogeneic activated cell therapy (do-ACT), ie, in vitro activated donor lymphocytes (ADL) precultured for 4 days with rhIL-2 and activated in vivo by adminismtion of rhIL-2, was given to patients with resistant relapse not responding to do-CT (Fig 1) . All allo-CT procedures, including rhIL-2 administration, were performed on an outpatient basis within 1 to 16 months (median, 4 months) after BMT, as soon as relapse was diagnosed. Donor PBL were obtained by blood aspiration (for small cell doses) or by apheresis using a Baxter CS-3000+ cell separator (Baxter, Deerfield, L). Cells were infused without further in vitro manipulation, except for removal of red blood cells in cases of major AB0 incompatibility. The cell dose given was calculated as the total number of T cells per kilogram. The cumulative number of T cells infused with donor PBL ranged from 0.2 X 108/kg to 4.6 X 108/kg; cell numbers per dose are listed in Tables 1 and 2 . Escalation of post-BMT immunotherapy was considered if no measurable response was observed within 1 month or whenever disease progression was documented.
Augmentation of cell therapy by administration of rhIL-2. For both in vivo and in vitro activation of donor PBL, rhIL-2 was used.
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It was purchased from EuroCetus/Chiron (Amsterdam, The Netherlands) and was provided as I mg Proleukin, equivalent t o 18 X l O h international units (IU). In vivo rhlL-2 was given subcutaneously on an outpatient basis at a dose of 6 X 10' IU/m'/d for 3 consecutive days, starting on the day of administration of donor PBL (allo-CT) or ADL (allo-ACT).
In vitro uctivation of donor PBL bv rhlL-2 (ADL). ADL were prepared by culturing donor PBL at a concentration of 2 X 10" mononuclear cells per milliliter in RPM1 1640 medium (Biological Industries, Beit Haemek, Israel) containing 100 U h L penicillin and 100 & n L streptomycin in 750-mL sterile culture flasks (Corning, Coming, NY). The culture medium was supplemented with 4%' heat inactivated human AB serum (after screening for hepatitis A, B,
and C and human immunodeficiency virus-l [HlV-I I). Cells were cultured in rhlL-2 at a concentration of 6,000 IU/mL for 4 days in a humidified S% CO2 incubator at 37°C. Cells were harvested. centrifuged, washed twice with Hank's balanced salt solution. and adjusted to a concentration of 2 X IOh/mL. ADL were administered by infusion with a nonfiltered intravenous set. Activation of cells was confirmed by immunophenotyping, measuring 'H-thymidine uptake and in vitro microcytotoxic activity using chromium-labeled natural killer cell (NK)-sensitive (K562) and NK-resistant (Daudi) target cell lines (data not shown) as previously described. '5 Assessnzent of response to cell therapy. The time interval from initiation of allo-CT to administration of rIL-2 together with the subsequent dose of donor-derived PBL or allo-ACT ranged between S2 and 206 days (median, 60 days; a median of 30 days from allo-CT to allo-CT + rhIL-2 and a median of 30 days from allo-CT + rhIL-2 and allo-ACT + rhIL-2). The effect of a h -C T and allo-ACT ? rhIL-2 on relapse was assessed by hematologic evaluation of disease-specific parameters, including blood and bone marrow morphology, cytogenetics (disease-specific translocations). and diseasespecific transcripts (bcr/abl by the reverse transcriptase-polymerase chain reaction [RT-PCR])." In addition, whenever applicable, hostand donor-specitic markers were determined (eg, presence of male cells in female-to-male chimeras) by cytogenetic analysis of phytohemagglutinin-stimulated PBL and spontaneous metaphases in bone marrow aspirates andlor by detection of male-specific molecular markers by PCR, using SRY or amelogenin-specific (AMG) oligonucleotide primers.'"."' Disease-free survival was reported for all a\-sessable cases.
Molecdur anulysis ufninirnul residual diseuse. Minimal residual disease was determined by detection of bath disease and hostspecific markers. Disappearance of previously positive RT-PCR or Y-specific host markers for a minimum of two consecutive tests at 2 I -month intervals after cell therapy was interpreted as evidence of elimination of minimal residual disease. RT-PCR for detection of bcrlabl was performed according to published methods.'x Detection of Y-specific markers was performed either by PCR of SRYspecific regions, as previously described,*' or by PCR of part of the AMG gene on the X-chromosome and its shorter copy Table 1 .
At 1 month post-BMT, his peripheral white blood cell count rose to 
1'
+rlL-2 +rlL-2 taneous masses of 2 cm in diameter and one additional retrotracheal mass of 3 cm in diameter that restricted the larynx, with symptomatic respiratow distress requiring tracheotomy. Cytogenetic analysis of the marrow and cells obtained from one of the masses showed male cells with the original clonal cytogenetic abnormality, with no evidence of Epstein-Barr virus (EBV), thus excluding post-BMT EBV-induced lymphoma. Emergency palliative systemic treatments included vincristine and prednisone, with low-dose methotrexate (20 mg/m2) and local irradiation (2,400 cGy) of the retrotracheal lesion and of one of the masses. Due to progressive hematologic relapse and extramyeloid lesions, the patient received a total of six doses of graded increments of donor (female) PBL equivalent to lo3, lo", lo5, 5 X lo5, 5 X lo5, and 1 X lo6 T cells per kilogram to induce GVL. On day +l02 post-BMT, the patient developed mild grade I acute cutaneous GVHD, which gradually progressed within 2 weeks to grade XI with involvement of the skin and liver with rapid response to prednisone (2 m a g ) . Surprisingly, a visible response was noted within 2 to 3 weeks; all masses gradually disappeared and blasts could no longer be detected. The patient was gradually tapered off steroids as soon as all cutaneous manifestations of GVHD regressed and liver function tests normalized. Remission was confirmed by normal bone marrow morphology and by cytogenetic analysis featuring normal female karyotype in 50 of 50 metaphases investigated. Continuous follow up of the patient showed normal growth and development. To date (more than 8 years after allo-CT), no residual male cells have been detected by PCR analysis with either SRY-specific or AMG-specific primers (sensitivity, 1:106 male cells).
On the basis of the successful outcome with the first patient, allo-CT given as graded increments of donor PBL (Fig  1) was administered to an additional cohort of 16 patients who had relapsed l to 16 months (median, 4 months) after BMT. As shown in Tables 1 and 2, only 5 of 17 patients (four with cytogenetic relapse and one with hematologic HLA matched sibling disease) had no detectable leukemic cells after allo-CT. Of 13 patients with overt hematologic relapse (four with CML, four with ALL, three with AML, one with Burkitt's lymphoma, and one with MDS with excess blasts), only one patient responded to allo-CT. Hence, cell therapy was escalated by rhIL-2 (see below). In contrast, all four patients with minimal cytogenetic relapse responded to donor PBL alone ( Table 2) .
IntensiJication of cell therapy with rhlL-2. Based on the cumulative preclinical data in murine models of acute lymphoid and myeloid l e~k e m i a s , '~~~~~" " ' we investigated the use of rhIL-2 administered in vivo and in vitro to increase GVL effects, as presented in Fig 1. Eleven patients who had not responded to allo-CT (excluding one patient, UPN 5 17 in Table 1 , where disease progression occurred before therapy could be initiated) were given rhIL-2 in vivo for 3 days after infusion with donor PBL. Allo-ACT, ie, combining in vitro activation of donor PBL (ADL) with additional in vivo activation of GVL effects by rhIL-2 for 3 consecutive days after infusion with ADL, was tested in five patients who did not respond to infusion with donor PBL and rhIL-2 alone and who had not developed GVHD (Table 1) . As can be seen in Tables 1 and 2 , relapse after BMT was successfully reversed in 10 of the 17 patients: in four of six with ALL, none of three with AML, five of six with CML, and one patient with MDS with excess blasts (one of two cases with other syndromes). Of six patients with overt hematologic relapse who responded to cell therapy, five patients were induced into remission only after additional activation of donor PBL with rhIL-2. As detailed above, the time interval from induction of immunotherapy by donor-derived T cells alone and donor T cells activated by rhIL-2 (in vivo, in vitro, or both) ranged between 52 and 206 days (median, 60 days).
At present, all four responders with ALL and four of the five patients with CML (one of whom was transplanted in accelerated phase) are alive and well, free of disease 17 to 96 months (median, 38 months) after BMT and more than For personal use only. on October 27, 2017. by guest www.bloodjournal.org From 13 to 95 months (median, greater than 2 years) after cell therapy. One of the responders with CML died of GVHD grade IV with no evidence of disease (Table 2) , while another responder with MDS treated in transition to overt leukemia died of late relapse ( Table 1) . Two of the four patients with CML with extremely resistant relapse received additional posttransplant immunotherapy to maintain remission; one patient treated at accelerated phase (UPN 244) received additional rhIL-2 and aIFN therapy for 2 months. Patient N.L. with adult-type CML at the age of 9 years, who was originally treated with a non-T cell-depleted graft in Seattle, WA, received aIFN after completing allo-CT and allo-ACT. Currently, all four patients are persistently negative for bcr/ abl, according to RT-PCR with no evidence of GVHD and a Karnofsky score of 100%. Of the four responding patients with ALL, the first (UPN 138), whose case report is described here in detail, has no evidence of GVHD, while two patients (G.R. and UPN 564) have moderate and mild chronic GVHD, respectively. All are free of disease.
DISCUSSION
Although relapse after BMT is generally considered incurable, we present a successful treatment for resistant, relapsing acute and chronic leukemia by posttransplant immunotherapy with donor immunocompetent PBL with a follow-up period of greater than 8 years. Interestingly, in agreement with preclinical experiments in murine models of donor PBL were amplified in vivo by a short course of rhIL-2 administrated subcutaneously with no severe side reactions. With a standard BMT protocol, even in patients at risk of developing GVHD, the incidence of relapse may reach 25% when patients are transplanted in first complete remission, nearly 50% at more advanced disease, and greater than 75% in patients transplanted in overt relapse or with resistant petent T lymphocytes present in the donor marrow aspirate may be insufficient to prevent relapse when conventional anti-GVHD prophylaxis is admini~tered.~~"~ Indeed, it was previously documented that posttransplant immunosuppression for prevention, attenuation, or treatment of GVHD, unavoidable after non-T cell-depleted BMT, may also abrogate the T cell-dependent GVL e f f e~t s '~-~l in experimental anim a l~~* and human^.^^.'^ Conversely, it was also shown that discontinuation of cyclosporin A as soon as relapse is diagnosed can reinduce remi~sion.'"~'
In our own study, we found that of the 17 patients treated by cell therapy, 6 of the 10 responders developed GVHD, whereas in the remaining four responders, GVL was independent of GVHD. Of the seven nonresponders, only one developed GVHD, pointing to the close relationship between GVL and GVHD. Furthermore, GVL can occur independently of GVHD, whereas GVHD may not be sufficient to induce effective GVL. The 40% success rate among responders without GVHD indicates that GVL can be induced by increasing the intensity of all~-CT.~"*~ Nonetheless, as the time to remission induction in patients relapsing after BMT in response to allo-CT may take longer than the median of 60 days elapsed between administration of donor-derived ALL and AML,l7.'9,30-.'.' the antileukemic effects induced by disease.l-7.34.'5 Hence, GVL effects induced by immunocom-PBL and rhIL-2-dependent immunotherapy (range, 52 to 206 days), the conclusion that remission was induced by rIL-2-activated donor T lymphocytes rather than being ; I late response to allo-CT alone must be kept in mind.
The cumulative international experience with allo-CT in a total of 163 confirms our initial observations. Complete responses (molecular, cytogenetic; or hematologic) were observed in 98 of 158 (62.8%) assessable patients (72% among patients with CML and 45% among patients with other hematologic malignancies). Allo-CT proved effective in treating relapse after both unmanipulated and T cell-depleted BMT for different hematologic malignanCies47.6' ' Independently of prior aIFN therapy. Remission in most, but not all, cases successfully treated with allo-CT was linked to GVHD, which was observed in 63% of assessable patients with CML and 39% of assessable patients with other hematologic malignan~ies,"~~~~"~"~~' suggesting that remission may be induced with no GVHD.4'.M' According to our own data and in agreement with other relapse was less successfully reversed in acute leukemia when compared with CML: 45.4% versus 83.3%. respectively. However, effective treatment of 6 of the 13 patients in advanced hematologic relapse, five of whom received rhIL-2 after failing allo-CT alone, indicates that the success rate may be increased in patients with acute leukemia as well as in patients with CML by additional activation of donor PBL with rhIL-2 in vivo andlor in vitro.
Based on earlier animal datahx and on the results of this study, infusion with graded increments of donor PBL may be an individually adaptable, safe, simple, and cost-effective method of inducing GVL while controlling the incidence, intensity, and severity of GVHD. At early evidence of molecular or cytogenetic relapse, or to prevent relapse in high-risk cases, allo-CT may be considered with a low, relatively safe, initial cell dose of lo5 T cells per kilogram to avoid severe GVHD. A 10-fold increase can then be given at 2 to 4-week intervals to patients receiving no anti-GVHD prophylaxis who do not develop GVHD." As shown in Table 2 , patients with minimal residual disease responded very effectively to small increments of donor PBL without any need for more aggressive immunotherapy (eg, high donor cell doses or rhIL-2) and with no signs of marrow aplasia.
T cell-dependent GVL effects independent of GVHD have previously been reported in experimental animals""'~" and humans. The capacity of lymphocytes fully tolerant to hosttype alloantigens to mediate GVL independently of GVHD is strongly supported by data in m i~e . ' *~'~. '~~~" Moreover, we have recently documented that high-dose rhIL-2 may induce GVL-like effects even after syngeneic BMT.7' Interestingly, T cells with potential specific reactivity to tumor cells rather than normal host cells were documented in different experimental system^,"^^^ supporting a possible cellular basis for GVL independently of GVHD.7"
In support of our concept that amplified GVL while controlling for GVHD may be accomplished by administration of graded increments of donor cells late after BMT, we have previously documented the safety of graded increments of immunocompetent allogeneic donor-type T cells in stable chimeras after non-T cell-depleted,6x as well as after T cell- Graded increments of donor PBL administered late after BMT may account for improved outcome in our study as compared with data reported by Sullivan et al. 76 These investigators could not document any benefit in response to early administration of large inocula of donor PBL to recipients of non-T cell-depleted allografts in patients receiving posttransplant immunosuppression.
Based on our observations, we would like to hypothesize that transplant-related complications due to severe GVHD and postgrafting immunosuppressive agents may be partly prevented by combining T cell depletion at BMT with avoiding posttransplant immunosuppressive therapy, which is mandator-after a non-T cell-depleted BMT procedure. Late administration of graded increments of donor PBL, while controlling for GVHD, may be used at a later stage for prevention of relapse.
As shown in experimental animals and as suggested by the cumulative clinical experience, induction of optimal cellmediated immunotherapy to treat occult residual tumor cells escaping chemoradiotherapy or relapsing disease may be best accomplished under no cover of post-BMT immunosuppressive agents, with control of GVHD by optimal timing, starting as late as possible, followed by modest increments of donor T cell number, with both procedures adapted to the unique sensitivity and needs of each individual. For patients in complete remission, T cell-depleted BMT (avoiding GVHD and the need for post-BMT immunosuppression) with compensatory T-cell repletion by a safe allo-CT regimen should be further investigated prospectively as a possible alternative to the conventional BMT protocol. For patients with primary resistant disease or overt relapse post-BMT, a non-T cell-depleted allograft may be preferable, despite the risk of GVHD, to prevent early and irreversible progression of leukemia. In principle, allo-CT may be also considered for recipients of non-T cell-depleted allografts who are off immunosupressive therapy with stable condition and no evidence of GVHD, thus further increasing the chance of elimination of host-derived tumor cells as well as residual normal hematopoietic cells. Increments of donor PBL should be considered until elimination of all measurable tumor cells or residual host cells as determined by sensitive molecular tools (eg, PCR, RT-PCR, or PCR-variable number tandem repeats [VNTR]) or until GVHD is imminent. As a rule, aggressive, thus more risky, posttransplant immunotherapy should be considered only if disease or host-specific markers persist or reappear. Nonetheless, based on the above concepts, the clinical application of a nonaggressive allo-CT protocol, using a low and slow donor T-cell therapy regimen for prevention rather than for treatment of measurable disease, may be justified in a prospective randomized clinical trial in patients at risk to relapse, as has recently been successfully pioneered at our center.69
In conclusion, although patients with a variety of hematologic malignancies relapsing after BMT, especially CML, may be successfully treated with allo-CT, patients resistant to therapy with donor cells alone might still respond to allo-CT and allo-ACT enhanced by rhIL-2 administration in vivo. Alloimmune-mediated interactions between immunocompetent donor T cells and residual tumor cells of host origin should be used for patients receiving no immunosuppressive agents to prevent GVHD. The efficacy of immunotherapy as described here and the lack of a safe alternative modality for treating relapse after BMT suggest that allogeneic cell therapy with matched donor PBL may become an important tool for the treatment of hematologic malignancies, based on alloimmune recognition of host tumor cells as minor histocompatibility-mismatched allografts. The possible use of allogeneic cell therapy for prevention rather than treatment of relapse for a wider range of malignancies should be further investigated. 
